[SCHEDULE 13D/A] BIO-RAD LABORATORIES, INC. SEC Filing

Rhea-AI Filing Summary

Bio-Rad Laboratories (BIO): A Schedule 13D/A (Amendment No. 9) updates the Schwartz family’s beneficial ownership and control of the company’s Class B Common Stock following the passing of Alice N. Schwartz on September 25, 2025. Norman D. Schwartz became sole trustee of the relevant trusts.

Blue Raven Partners, L.P. directly holds 4,060,054 Class B shares, representing 80.1% of the class. Norman D. Schwartz is deemed to beneficially own 4,929,036 Class B shares (97.2%), including shares held directly and via trusts, and indirect interests through the partnership. Steven D. Schwartz is deemed to beneficially own 4,098,294 Class B shares (80.8%). Class B shares outstanding were 5,070,184 as of July 28, 2025.

The filing states the purpose of the Shareholders’ ownership has been control of the company, and that by virtue of their Class B holdings they control management. The amendment also lists recent option exercises and gifts among the reporting persons and notes that Alice N. Schwartz’s trust holds 437,510 Class B shares (8.6%).

Insights

Equity ownership & governance analyst

Update confirms Class B control concentrated with Schwartz affiliates.

The amendment formalizes post-estate changes: Norman D. Schwartz becomes sole trustee for the relevant trusts after September 25, 2025. Control remains anchored by Blue Raven Partners with 80.1% of Class B and Norman’s deemed beneficial ownership at 97.2%, reflecting direct, trust, and partnership interests.

Because Class B typically carries enhanced voting relative to Class A, the reported 80.1% Class B stake supports continued control. The filing also details gifts and option exercises without indicating changes to the control thesis. Actual governance impact relies on the dual-class structure as disclosed by the issuer.

The filing specifies outstanding counts—Class B at 5,070,184 as of July 28, 2025—which anchor the percentages. Subsequent disclosures may further detail any estate-related distributions, but this amendment states the control purpose and current concentrations.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 9)

Bio-Rad Laboratories, Inc.

(Name of Issuer)

Class B Common Stock

(Title of Class of Securities)

090572207

(CUSIP Number)

Norman D. Schwartz
1000 Alfred Nobel Drive,
Hercules, CA, 94547
5107247000

Courtney C. Enloe
Bio-Rad Laboratories, Inc, 1000 Alfred Nobel Drive
Hercules, CA, 94547
5107416005

John Duke
Hogan Lovells US LLP, 1735 Market Street, Suite 2300
Philadelphia, PA, 19103
2676754616

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

09/25/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 090572207

1

Name of reporting person

Norman D. Schwartz

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 868,982.00
8	Shared Voting Power 4,060,054.00
9	Sole Dispositive Power 868,982.00
10	Shared Dispositive Power 4,060,054.00

11

Aggregate amount beneficially owned by each reporting person

4,929,036.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

97.2 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

(7)(8) (9) 494,510 of the reported securities are held by the following trusts, both of which Norman D. Schwartz is the sole trustee: the David Schwartz Non-Exempt Marital Trust (57,000 shares); and the Alice N. Schwartz Revocable Trust (437,510 shares). Prior to her death, Alice N. Schwartz was the sole trustee of the aforementioned trusts. Upon her death, Norman D. Schwartz, Chief Executive Officer and Chairman of the Board of Directors of Bio-Rad, became the sole trustee of such trusts. Includes 374,472 shares held by Norman D. Schwartz but he disclaims beneficial ownership with respect to 13,006 of such shares owned by his wife.

SCHEDULE 13D

CUSIP No. 090572207

1

Name of reporting person

Steven D. Schwartz

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 38,240.00
8	Shared Voting Power 4,060,054.00
9	Sole Dispositive Power 38,240.00
10	Shared Dispositive Power 4,060,054.00

11

Aggregate amount beneficially owned by each reporting person

4,098,294.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

80.8 %

14

Type of Reporting Person (See Instructions)

IN

Comment for Type of Reporting Person:

(7)(9) (11) Includes 13,006 shares owned by Steven D. Schwartz's wife, as to which he disclaims beneficial ownership

SCHEDULE 13D

CUSIP No. 090572207

1

Name of reporting person

Blue Raven Partners, L.P.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CALIFORNIA

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 4,060,054.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 4,060,054.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

4,060,054.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

80.1 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP No. 090572207

1

Name of reporting person

Alice N. Schwartz Revocable Trust

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CALIFORNIA

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 437,510.00
8	Shared Voting Power 0.00
9	Sole Dispositive Power 437,510.00
10	Shared Dispositive Power 0.00

11

Aggregate amount beneficially owned by each reporting person

437,510.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

8.6 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Class B Common Stock
(b)	Name of Issuer: Bio-Rad Laboratories, Inc.
(c)	Address of Issuer's Principal Executive Offices: 1000 Alfred Nobel Drive, Hercules, CALIFORNIA , 94547.
Item 1 Comment: Reference is made to the statement on Schedule 13D filed with the Securities and Exchange Commission (the "Commission") on January 13, 2000 by David Schwartz, Alice N. Schwartz, Norman D. Schwartz, Steven D. Schwartz and Blue Raven Partners, L.P., as amended by Amendment No. 1 to the statement on Schedule 13D filed with the Commission on June 27, 2003, Amendment No. 2 to the statement on Schedule 13D filed with the Commission on March 22, 2005, Amendment No. 3 to the statement on Schedule 13D filed with the Commission on July 31, 2007, Amendment No. 4 to the statement on Schedule 13D filed with the Commission on August 27, 2009, Amendment No. 5 to the statement on Schedule 13D filed with the Commission on November 15, 2013, Amendment No. 6 to the statement on Schedule 13D filed with the Commission on June 29, 2017, Amendment No. 7 to the statement on Schedule 13D filed with the Commission on July 12, 2019, and Amendment No. 8 to the statement on Schedule 13D filed with the Commission on April 11, 2022 by Alice N. Schwartz, Norman D. Schwartz, Steven D. Schwartz, Blue Raven Partners, L.P. and the Alice N. Schwartz Revocable Trust (the "Prior Filing"). Each of Norman D. Schwartz and Steven D. Schwartz together with Blue Raven Partners, L.P. and the Alice N. Schwartz Revocable Trust (sometimes collectively referred to as the "Shareholders") has agreed to file this statement jointly in an agreement entered into pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, and included as an exhibit to this statement, which agreement is hereby incorporated by reference. The Prior Filing is incorporated herein by reference and is hereby amended by this statement which is filed by the Shareholders, with respect to whom the following information relates. Alice N. Schwartz, a former Director Emeritus of Bio-Rad and a reporting person in the Prior Filing, passed away on September 25, 2025. Upon her death, Norman D. Schwartz became the sole trustee of the Alice N. Schwartz Revocable Trust.
Item 2.	Identity and Background
(a)	Norman D. Schwartz, Chief Executive Officer and Chairman of the Board of Directors of Bio-Rad, Steven D. Schwartz, an employee of Bio-Rad, Blue Raven Partners, L.P. (the "Partnership"), a California limited partnership organized to provide consolidated management of certain assets owned by the partners, and the Alice N. Schwartz Revocable Trust.
(b)	1000 Alfred Nobel Drive Hercules, California 94547 (510) 724-7000
(c)	Norman D. Schwartz, Chief Executive Officer and Chairman of the Board of Directors of Bio-Rad, Steven D. Schwartz, an employee of Bio-Rad, Blue Raven Partners, L.P. (the "Partnership"), a California limited partnership organized to provide consolidated management of certain assets owned by the partners, and the Alice N. Schwartz Revocable Trust.
(d)	During the last five years, none of Norman D. Schwartz, Steven D. Schwartz, the Partnership and the Alice N. Schwartz Revocable Trust has been convicted in a criminal proceeding (excluding traffic violations and similar misdemeanors) or has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
(f)	United States of America
Item 3.	Source and Amount of Funds or Other Consideration
	Item 3 to the Schedule 13D is hereby amended, in pertinent part, as follows: Norman D. Schwartz Due to the death of Alice N. Schwartz, Norman D. Schwartz acquired beneficial ownership of the shares held in the David Schwartz Non-Exempt Marital Trust and the Alice N. Schwartz Revocable Trust, as he became the sole trustee of such trusts upon the death of his mother. Since the most recent filing of a statement on Schedule 13D, the following transactions have been effected by Norman D. Schwartz. Date: 8/26/2022*; Shares: 15,501; Type: Stock option exercise; Price: $107.32; Ownership: Direct Date: 11/7/2022 ; Shares: 84; Type: Gift; Price: --; Ownership: Direct Date: 8/25/2023*; Shares: 13,611; Type: Stock option exercise; Price: $117.50; Ownership: Direct Date: 11/1/2023*; Shares: 9,358; Type: Stock option exercise; Price: $119.80; Ownership: Direct Date: 11/1/2023*; Shares: 3,726; Type: Stock option exercise; Price: $139.56; Ownership: Direct Date: 11/1/2023*; Shares: 2,976; Type: Stock option exercise; Price: $159.32; Ownership: Direct Date: 12/5/2023 ; Shares: 98; Type: Gift; Price: --; Ownership: Direct Date: 8/26/2024 ; Shares: 114; Type: Gift; Price: --; Ownership: Direct Footnotes * Acquired through net share settlement. The shares of Class B Common Stock acquired on November 7, 2022, December 5, 2023 and August 26, 2024 were acquired by Norman D. Schwartz and his wife in equal amounts of one half each by gift from the Alice N. Schwartz Revocable Trust. Steven D. Schwartz Since the most recent filing of a statement on Schedule 13D, the following transactions have been effected by Steven D. Schwartz. Date: 11/7/2022 ; Shares: 84; Type: Gift; Price: --; Ownership: Direct Date: 12/5/2023 ; Shares: 98; Type: Gift; Price: --; Ownership: Direct Date: 8/26/2024 ; Shares: 114; Type: Gift; Price: --; Ownership: Direct The shares of Class B Common Stock acquired on November 7, 2022, December 5, 2023 and August 26, 2024 were acquired by Steven D. Schwartz and his wife in equal amounts of one half each by gift from the Alice N. Schwartz Revocable Trust. Alice N. Schwartz Revocable Trust Since the most recent filing of a statement on Schedule 13D, the following transactions have been effected by the Alice N. Schwartz Revocable Trust. Date: 11/7/2022 ; Shares: (252); Type: Gift; Price: --; Ownership: Direct Date: 12/5/2023 ; Shares: (294); Type: Gift; Price: --; Ownership: Direct Date: 8/26/2024 ; Shares: (342); Type: Gift; Price: --; Ownership: Direct
Item 4.	Purpose of Transaction
	Item 4 to the Schedule 13D is hereby amended, in pertinent part, as follows: The purpose of the Shareholders' ownership of Bio-Rad shares has been control of the Company. The Shareholders control the management of the Company and may be deemed to be "parents" of the Company as that term is defined in the Rules and Regulations of the Commission.
Item 5.	Interest in Securities of the Issuer
(a)	Item 5 to the Schedule 13D is hereby amended, in pertinent part, as follows: (a)-(b) The Partnership: The Partnership is the direct and beneficial owner of 4,060,054 shares of the Class B Common Stock with respect to which it has sole voting and dispositive power, representing 80.1% of the issued and outstanding Class B Common Stock. Norman D. Schwartz and Steven D. Schwartz: Norman D. Schwartz and Steven D. Schwartz have indirect beneficial ownership of the 4,060,054 shares of Class B Common Stock held by the Partnership, over which they have shared voting and dispositive power, as the result of their positions as general partners in the Partnership. Norman D. Schwartz is the beneficial owner of 868,982 shares of Class B Common Stock. 494,510 of such shares of Class B Common Stock are held in the following trusts, both of which Mr. Schwartz is the sole trustee: the David Schwartz Non-Exempt Marital Trust (57,000 shares); and the Alice N. Schwartz Revocable Trust (437,510 shares). Prior to her death, Alice N. Schwartz was the sole trustee of the aforementioned trusts. Upon her death, Norman D. Schwartz became the sole trustee of such trusts. In addition, Mr. Schwartz holds 374,472 shares of Class B Common Stock but disclaims beneficial ownership with respect to 13,006 of such shares owned by Mr. Schwartz's wife. As a result of the foregoing, Mr. Schwartz is deemed to have beneficial ownership of an aggregate of 4,929,036 shares of Class B Common Stock, representing 97.2% of the issued and outstanding Class B Common Stock. Steven D. Schwartz holds 38,240 shares of Class B Common Stock but disclaims beneficial ownership with respect to 13,006 of such shares owned by Steven D. Schwartz's wife. As a result of the foregoing, Steven D. Schwartz is deemed to have beneficial ownership of an aggregate of 4,098,294 shares of Class B Common Stock, representing 80.8% of the issued and outstanding Class B Common Stock. The Alice N. Schwartz Revocable Trust is the direct and beneficial owner of 437,510 shares of Class B Common Stock with respect to which it has sole voting and dispositive power, representing 8.6% of the issued and outstanding Class B Common Stock. All percentages reported herein with respect to Class B Common Stock are calculated based upon 5,070,184 shares of Class B Common Stock outstanding as of July 28, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on July 31, 2025.
(c)	Not applicable
(d)	Not applicable
(e)	Due to the death of Mrs. Alice N. Schwartz, on September 25, 2025, Ms. Schwartz ceased to be a beneficial owner of more than 5% of the outstanding shares of Class B Common Stock of the Company.
Item 6.	Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer
	Item 6 to the Schedule 13D is hereby amended, in pertinent part, as follows: Norman D. Schwartz owns beneficially 3,228,922 shares of Class A Common Stock, representing 14.6% of the issued and outstanding Class A Common Stock. 2,714,928 of these shares are held by the following trusts, all of which Norman D. Schwartz is the sole trustee: the David and Alice N. Schwartz Charitable Remainder Unitrust (34,311 shares); the David Schwartz Exemption Trust (90 shares); the David Schwartz Exempt Marital Trust (240 shares); the David Schwartz Non-Exempt Marital Trust (898,931 shares); and the Alice N. Schwartz Revocable Trust (1,781,356 shares). 17,145 of these shares are held by the Alles Institute for Medical Research, a Delaware Charitable Nonstock Corporation, with respect to which Norman D. Schwartz shares voting and dispositive power consistent with the purposes of the Delaware Charitable Nonstock Corporation. Steven D. Schwartz holds 380,789 shares of Class A Common Stock, but disclaims beneficial ownership with respect to 1,498 of such shares owned by Steven D. Schwartz's wife. Steven D. Schwartz's shares of Class A Common Stock represent approximately 1.7% of the issued and outstanding Class A Common Stock. 17,145 of these shares are held by the Alles Institute for Medical Research, a Delaware Charitable Nonstock Corporation, with respect to which Steven D. Schwartz shares voting and dispositive power consistent with the purposes of the Delaware Charitable Nonstock Corporation. The Alice N. Schwartz Revocable Trust holds 1,781,356 shares of Class A Common Stock, representing 8.2% of the issued and outstanding Class A Common Stock. Norman D. Schwartz and Steven D. Schwartz are brothers. By virtue of the Shareholders' Class B Common Stock ownership, they control the management of the Company and may be deemed to be "control persons" of the Company as that term is defined in the Rules and Regulations of the Commission. All percentages reported herein with respect to Class A Common Stock are calculated based upon 21,992,307 shares of Class A Common Stock outstanding as of July 28, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on July 31, 2025. For Norman D. Schwartz, the beneficial ownership calculation with respect to Class A Common Stock is calculated by using a denominator of (a) 21,992,307 shares of Class A Common Stock plus (b) 53,415 shares of Class A Common Stock issuable upon the exercise of stock options exercisable by Mr. Schwartz immediately or within sixty days of September 25, 2025.
Item 7.	Material to be Filed as Exhibits.
	Exhibit 1 - Agreement Among the Shareholders to File Joint Schedule 13D Exhibit 2*- Limited Partnership Agreement of Blue Raven Partners, L.P. *Incorporated by reference to Exhibit 2 to our Schedule 13D filed with the Commission on January 13, 2000

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Norman D. Schwartz

Signature:	/s/ Norman D. Schwartz
Name/Title:	Norman D. Schwartz, Individually
Date:	10/28/2025

Steven D. Schwartz

Signature:	/s/ Steven D. Schwartz
Name/Title:	Steven D. Schwartz, Individually
Date:	10/28/2025

Blue Raven Partners, L.P.

Signature:	/s/ Norman D. Schwartz
Name/Title:	Norman D. Schwartz, General Partner
Date:	10/28/2025

Alice N. Schwartz Revocable Trust

Signature:	/s/ Norman D. Schwartz
Name/Title:	Norman D. Schwartz, Trustee
Date:	10/28/2025

FAQ

What did Bio-Rad (BIO) disclose in this Schedule 13D/A?

An update to beneficial ownership of Class B Common Stock by the Schwartz family and affiliates, reflecting trustee changes after September 25, 2025, and confirming control intent.

How much Class B stock does Blue Raven Partners hold in BIO?

Blue Raven Partners, L.P. holds 4,060,054 Class B shares, representing 80.1% of the class.

What is Norman D. Schwartz’s beneficial ownership in BIO Class B?

Norman D. Schwartz is deemed to beneficially own 4,929,036 Class B shares, or 97.2% of the class.

What is Steven D. Schwartz’s beneficial ownership in BIO Class B?

Steven D. Schwartz is deemed to beneficially own 4,098,294 Class B shares, or 80.8% of the class.

How many Bio-Rad Class B shares were outstanding, and as of when?

Class B shares outstanding were 5,070,184 as of July 28, 2025.

What is the stated purpose of the shareholders’ ownership?

The filing states the purpose has been control of the Company, and that their Class B ownership allows them to control management.

Were there recent transactions noted among the reporting persons?

Yes. The amendment lists stock option exercises and gifts in 2022–2024 by Norman and Steven D. Schwartz and related trust gifts.